Flavone acetic acid: a nonlinear pharmacokinetic model
- PMID: 3409441
- DOI: 10.1007/BF00257307
Flavone acetic acid: a nonlinear pharmacokinetic model
Abstract
Flavone acetic acid pharmacokinetics were studied in 31 patients in a phase I clinical trial. The drug was given by i.v. infusions over 1, 1.5, 3, and 6 h at doses ranging from 0.5 to 6.4 g/m2. The pharmacokinetic parameters were determined according to a nonlinear model including Michaelis-Menten-type kinetics. The mean elimination half-life is 4.8 h and the mean volume of distribution of the central compartment, 7.61. Our model predicted a maximal tolerated dose (MTD) of 11.1 g/m2 on the basis of the "therapeutic window" concept, very close to the clinically observed MTD of 10 g/m2. This model is also operational when different protocols of inoculation are considered, such as a divided-dose schedule vs a unique infusion, and indicates that, at the MTD, injections should be made every 72 h to avoid drug accumulation.
Similar articles
-
Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512).Cancer Res. 1988 Oct 15;48(20):5878-82. Cancer Res. 1988. PMID: 3167843
-
Phase I and pharmacokinetic study of flavone acetic acid.Cancer Res. 1987 Dec 15;47(24 Pt 1):6776-81. Cancer Res. 1987. PMID: 3677106
-
Phase I clinical and pharmacokinetic trial of flavone acetic acid.J Natl Cancer Inst. 1991 Jan 16;83(2):124-8. doi: 10.1093/jnci/83.2.124. J Natl Cancer Inst. 1991. PMID: 1703237 Clinical Trial.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Flavone acetic acid--preclinical and clinical activity.Eur J Cancer Clin Oncol. 1989 Sep;25(9):1271-2. doi: 10.1016/0277-5379(89)90072-2. Eur J Cancer Clin Oncol. 1989. PMID: 2680512 Review. No abstract available.
Cited by
-
Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.Br J Cancer. 1992 Sep;66(3):579-82. doi: 10.1038/bjc.1992.317. Br J Cancer. 1992. PMID: 1520597 Free PMC article. Clinical Trial.
-
A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.Cancer Chemother Pharmacol. 1992;29(5):354-60. doi: 10.1007/BF00686003. Cancer Chemother Pharmacol. 1992. PMID: 1551173
-
Flavone acetic acid distribution in human malignant tumors.Cancer Chemother Pharmacol. 1990;26(1):67-70. doi: 10.1007/BF02940298. Cancer Chemother Pharmacol. 1990. PMID: 2322990
-
Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.Cancer Chemother Pharmacol. 1991;28(6):409-13. doi: 10.1007/BF00685815. Cancer Chemother Pharmacol. 1991. PMID: 1934244
-
Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics.J Pharmacokinet Biopharm. 1993 Dec;21(6):639-51. doi: 10.1007/BF01113499. J Pharmacokinet Biopharm. 1993. PMID: 8138891 Clinical Trial.